The anti-hepatocellular carcinoma effect of Brucea javanica oil in ascitic tumor-bearing mice: The detection of brusatol and its role.


Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 24 09 2020
revised: 30 11 2020
accepted: 07 12 2020
pubmed: 20 12 2020
medline: 20 7 2021
entrez: 19 12 2020
Statut: ppublish

Résumé

Brucea javanica oil (BJO), one of the main products of Brucea javanica, has been widely used in treating different kinds of malignant tumors. Quassinoids are the major category of anticancer phytochemicals of B. javanica. However, current researches on the anti-cancer effect of BJO mainly focused on oleic acid and linoleic acid, the common major components of dietary edible oils, essential and characteristic components of B. javanica like quassinoids potentially involved remained unexplored. In the current investigation, we developed an efficient HPLC method to detect brusatol, a characteristic quassinoid, and comparatively scrutinized the anti-hepatocellular carcinoma (anti-HCC) effect of BJO, brusatol-free BJO (BF-BJO), and brusatol-enriched BJO (BE-BJO) against hepatoma 22 (H22) in mice. High-performance liquid chromatography (HPLC) was utilized to identify the components in BJO. BE-BJO was extracted with 95 % ethanol. The anti-tumor effect of BJO, BF-BJO and BE-BJO was comparatively investigated, and the potential underlying mechanism was explored in H22 ascites tumor-bearing mice. The results indicated that BJO and BE-BJO significantly prolonged the survival time of H22 ascites tumor-bearing mice, while BF-BJO exhibited no obvious effect. BJO and BE-BJO exhibited pronounced anti-HCC activity by suppressing the growth of implanted hepatoma H22 in mice, including ascending weight, abdominal circumference, ascites volume and cancer cell viability, with a relatively wide margin of safety. BJO and BE-BJO significantly induced H22 cell apoptosis by upregulating the miRNA-29b gene level and p53 expression. Furthermore, BJO and BE-BJO treatment substantially downregulated Bcl-2 and mitochondrial Cytochrome C protein expression, and upregulated expression levels of Bax, Bad, cytosol Cytochrome C, caspase-3 (cleaved), caspase‑9 (cleaved), PARP and PARP (cleaved) to induce H22 cells apoptosis. Brusatol was detected in BJO and found to be one of its major active anti-HCC components, rather than fatty acids including oleic acid and linoleic acid. The anti-HCC effect of BJO and BE-BJO was intimately associated with the activation of miRNA-29b, p53-associated apoptosis and mitochondrial-related pathways. Our study gained novel insight into the material basis of BJO in the treatment of HCC, and laid a foundation for a novel specific standard for the quality evaluation of BJO and its commercial products in terms of its anti-cancer application.

Identifiants

pubmed: 33341052
pii: S0753-3322(20)31315-9
doi: 10.1016/j.biopha.2020.111122
pii:
doi:

Substances chimiques

Antineoplastic Agents, Phytogenic 0
Apoptosis Regulatory Proteins 0
MIRN29 microRNA, mouse 0
MicroRNAs 0
Plant Oils 0
Quassins 0
Trp53 protein, mouse 0
Tumor Suppressor Protein p53 0
brusatol 14907-98-3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111122

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Tongtong Wang (T)

The First Affiliated Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, PR China; Shandong Qingdao No. 2 Health School, Qingdao, PR China.

Yaoxing Dou (Y)

School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, PR China.

Guoshu Lin (G)

School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, PR China.

Qiaoping Li (Q)

School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, PR China.

Juan Nie (J)

School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, PR China.

Baoyi Chen (B)

School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, PR China.

Jianhui Xie (J)

State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, PR China; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, PR China.

Ziren Su (Z)

School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, PR China.

Huifang Zeng (H)

The First Affiliated Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, PR China. Electronic address: gancaozhf@126.com.

Jiannan Chen (J)

School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, PR China. Electronic address: chenjiannan@gzucm.edu.cn.

Youliang Xie (Y)

School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, PR China. Electronic address: xieyl@gzucm.edu.cn.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH